Immunoliposomes with Simvastatin as a Potential Therapeutic in Treatment of Breast Cancer Cells Overexpressing HER2—An In Vitro Study
Lipophilic statins are promising candidates for breast cancer treatment. However, anticancer therapy requires much higher doses of statins than can be delivered orally, and such high doses are known to exert more adverse effects. The main objective of our study was to design a targeted, therapeutic...
Main Authors: | Lucyna Matusewicz, Joanna Podkalicka, Aleksander F. Sikorski |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-11-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/10/11/418 |
Similar Items
-
Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer
by: Rodallec A, et al.
Published: (2018-06-01) -
Generation of CHO Stable Cell Line Overexpressing HER2: an In Vitro Model for Breast Cancer
by: Akbar Hedayatizadeh-Omran, et al.
Published: (2015-07-01) -
Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients
by: Joanna Huszno, et al.
Published: (2016-03-01) -
Frequency of HER-2 over Expression in the Patients with Breast Cancer after Mastectomy
by: S kargar, et al.
Published: (2013-10-01) -
Evaluation of tumor malignancy in patients with HER-2 overexpression breast cancer after TCH and TAC neoadjuvant chemotherapy
by: Yong Zhou, et al.
Published: (2016-10-01)